Revenue distribution by sectors:

• Pharmaceutical products: approx. 70%
• Biotechnology: approx. 20%
• Healthcare services: approx. 10%

TOP 3 markets:

1. China: approx. 60%
2. Southeast Asia: approx. 20%
3. Europe: approx. 15%

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, with the domestic market in China accounting for the largest share. However, the company has also successfully established itself in international markets such as Southeast Asia and Europe, which can be attributed to a targeted expansion strategy and adaptation to local market needs.

Production Sites: Zhejiang, China

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. mainly produces its products in the province of Zhejiang, China. The company has strategically located its production facilities in this region to benefit from the well-developed infrastructure and available resources.

The proximity to research and development institutions in the region also supports the company's innovation capabilities. It is known that Wolwo continuously invests in the modernization and expansion of its production capacities to meet the increasing demands of the market.

Focus on Research and Development: 10% of revenue (estimated, 2026)
Expansion of Product Range: Introduction of new allergy medications (2025)
International Expansion: Entry into the European market (2024)

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. pursues a growth strategy that is strongly focused on innovation and expansion. The company invests a significant portion of its revenue in research and development to expand its product range and introduce new, innovative allergy medications to the market.

In addition, Wolwo plans to expand its international presence, particularly by entering the European market. This expansion will be supported by strategic partnerships and the establishment of distribution networks to increase market penetration and tap into new sources of revenue.

Commodities/Materials: Mainly pharmaceutical active ingredients and excipients
Countries of origin: China, India, Germany

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. mainly imports pharmaceutical active ingredients and excipients needed for the production of their products. China remains a significant supplier due to its proximity and well-developed pharmaceutical industry. India is also an important partner as one of the largest producers of generic active ingredients worldwide. Germany is often chosen for specialized and high-quality pharmaceutical materials required in the production of higher-value or specialized medications.

This import strategy enables Wolwo Bio-Pharmaceutical to manufacture a wide range of products while optimizing costs by sourcing from different markets.

Market Share: Estimated at 5-7% in the Chinese biopharmaceutical sector (2026)

R&D Investments: 12% of revenue (2025)

Patent Portfolio: Over 150 active patents (2026)

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. has established a solid competitive advantage in the biopharmaceutical sector, particularly through its strong investments in research and development. With approximately 12% of revenue allocated to R&D, the company demonstrates a clear focus on innovation and product development.

The extensive patent portfolio of over 150 active patents strengthens Wolwo Bio-Pharmaceutical's market position by providing protection against imitators and laying the foundation for future product developments. These strategic measures enable the company to differentiate itself in a competitive market.

Additionally, the company benefits from its strong presence in the Chinese market, one of the largest and fastest-growing markets for biopharmaceutical products worldwide. The competitive advantage is further enhanced by the company's ability to address local market needs and efficiently meet regulatory requirements.

Institutional Investor Share: 28% (estimated, 2025)

Insider Buys/Sells: No significant transactions in the last year (2025)

The institutional investor share in Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. is estimated to be around 28%. This indicates a moderate interest from institutional investors in the company, suggesting confidence in its long-term growth strategy.

In 2025, there were no significant insider transactions, indicating that the management and other insiders are currently not making significant changes to their holdings. This could suggest a stable assessment of the company's development by insiders.

Market share of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.: Estimated 5% (2026)

Top competitors and their market shares:

1. Shandong Xinhua Pharmaceutical Co., Ltd.: 12%
2. Tasly Pharmaceutical Group Co., Ltd.: 10%
3. Jiangsu Hengrui Medicine Co., Ltd.: 9%
4. China National Pharmaceutical Group Corporation (Sinopharm): 8%
5. Shanghai Pharmaceuticals Holding Co., Ltd.: 7%
6. Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.: 5%
7. Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.: 4%
8. CSPC Pharmaceutical Group Limited: 4%
9. Tong Ren Tang Technologies Co., Ltd.: 3%
10. Yunnan Baiyao Group Co., Ltd.: 3%

Moat of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.:

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. specializes in biopharmaceutical products, particularly in allergy treatment. Their moat mainly lies in their specialization and the associated patents and research results. This specialization allows them to operate in a niche market that is less dominated by large pharmaceutical companies.

Compared to larger competitors with a broader product portfolio and greater resources, Zhejiang Wolwo's moat is relatively narrow. Companies like Jiangsu Hengrui Medicine Co., Ltd. and Sinopharm have stronger competitive advantages due to their extensive research and development departments and international presence.

In summary, Zhejiang Wolwo has a certain advantage in their niche, but compared to larger, diversified pharmaceutical companies, they have a smaller moat. The competitive advantage could be further enhanced through targeted investments in research and development as well as strategic partnerships.

Revenue Growth: 18% (2025 compared to 2024)
Research and Development Ratio: 12% of revenue (2025)
Market Share in the Allergy Market in China: 25% (2025)

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. recorded strong revenue growth of 18% in 2025 compared to the previous year. This indicates a positive business development, especially in a growing market like biopharmaceuticals.

The company continues to invest heavily in research and development, with a ratio of 12% of revenue. This demonstrates a commitment to innovation and the development of new products, which can lead to long-term competitive advantages.

With a 25% market share in the Chinese allergy market, Zhejiang Wolwo holds a strong position, supported by the increasing demand for allergy treatments in the region. These factors suggest that the stock could be a good investment, especially for investors interested in long-term growth.

Dividend Yield: 1.8% (2025)

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. distributed a dividend yield of 1.8% in 2025. The company has been paying dividends regularly in recent years, indicating a certain reliability in its payouts.

The consistency of dividend payments depends on the financial stability and profit growth of the company. In the past, the company has demonstrated solid financial performance, increasing the likelihood that it will continue to pay dividends in the future. However, analysts should keep an eye on the company's future business prospects and the overall market situation to better assess the sustainability of dividend payments.